| [1] |
LI J Y, PANDIAN V, DAVIDSON P M, et al. Burden and attributable risk factors of non-communicable diseases and subtypes in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021[J]. Int J Surg, 2025, 111(3): 2385-2397. DOI: 10.1097/JS9. 0000000000002260.
|
| [2] |
XU Y, LU J L, LI M, et al. Diabetes in China part 1: epidemiology and risk factors[J]. Lancet Public Health, 2024, 9(12): e1089-e1097. DOI: 10.1016/S2468-2667(24)00250-0.
|
| [3] |
JIA W P, CHAN J C, WONG T Y, et al. Diabetes in China: epidemiology, pathophysiology and multi-omics[J]. Nat Metab, 2025, 7(1): 16-34. DOI: 10.1038/s42255-024-01190-w.
|
| [4] |
ZHANG N N, YU H, LIU T Z, et al. Bmal1 downregulation leads to diabetic cardiomyopathy by promoting Bcl2/IP3R-mediated mitochondrial Ca2+ overload[J]. Redox Biol, 2023, 64: 102788. DOI: 10.1016/j.redox.2023.102788.
|
| [5] |
ZHAO X D, LIU S W, WANG X, et al. Diabetic cardiomyopathy: Clinical phenotype and practice[J]. Front Endocrinol, 2022, 13: 1032268. DOI: 10.3389/fendo.2022.1032268.
|
| [6] |
CAI C, WU F, HE J, et al. Mitochondrial quality control in diabetic cardiomyopathy: from molecular mechanisms to therapeutic strategies[J]. Int J Biol Sci, 2022, 18(14): 5276-5290. DOI: 10.7150/ijbs.75402.
|
| [7] |
李晓文. 基于PI3K/AKT信号通路探讨糖心平胶囊治疗糖尿病心肌病药效及机制[D]. 北京: 中国中医科学院, 2021. DOI: 10.27658/d.cnki.gzzyy.2021.000016.
|
|
LI X W. Efficacy and mechanism of Tangxinping capsule in treatment of diabetic cardiomyopathy based on PI3K/AKT signaling pathway[D]. Beijing: China Academy of Chinese Medical Sciences, 2021. DOI: 10.27658/d.cnki.gzzyy.2021.000016.
|
| [8] |
黄鑫磊, 贾雪雯, 丁元庆. 葛根芩连汤临床应用进展[J]. 山东中医药大学学报, 2020, 44(2): 215-220. DOI: CNKI:SUN:SDYX.0.2020-02-021.
|
|
HUANG X L, JIA X W, DING Y Q. Review on clinical application of Gegen Qinlian decoction[J]. J Shandong Univ Tradit Chin Med, 2020, 44(2): 215-220. DOI: CNKI:SUN:SDYX.0.2020-02-021.
|
| [9] |
孙洪平, 张会峰, 陈煜, 等. 葛根芩连汤调控FoxO1/MARCH1通路对小鼠胰岛素抵抗的改善作用[J]. 中成药, 2024, 46(5): 1662-1667. DOI: 10.3969/j.issn.1001-1528.2024.05.041.
|
|
SUN H P, ZHANG H F, CHEN Y, et al. Effect of Gegen Qinlian decoction on improving insulin resistance in mice by regulating FoxO1/MARCH1 pathway[J]. Chin Tradit Pat Med, 2024, 46(5): 1662-1667. DOI: 10.3969/j.issn.1001-1528.2024.05.041.
|
| [10] |
刘莲萱, 吴威, 庞琳琳, 等. 葛根芩连汤化学成分、药理作用及临床应用研究进展[J]. 中华中医药学刊, 2022, 40(3): 147-154. DOI: 10.13193/j.issn.1673-7717.2022.03.034.
|
|
LIU L X, WU W, PANG L L, et al. Research progress on chemical composition, pharmacological action and clinical application of Gegen Qinlian decoction[J]. Chin Arch Tradit Chin Med, 2022, 40(3): 147-154. DOI: 10.13193/j.issn.1673-7717.2022.03.034.
|
| [11] |
DILLMANN W H. Diabetic cardiomyopathy[J]. Circ Res, 2019, 124(8): 1160-1162. DOI: 10.1161/CIRCRESAHA.118.314665.
|
| [12] |
NAKAMURA K, MIYOSHI T, YOSHIDA M, et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus[J]. Int J Mol Sci, 2022, 23(7): 3587. DOI: 10.3390/ijms23073587.
|
| [13] |
MARGULIES K B, HERNANDEZ A F, REDFIELD M M, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2016, 316(5): 500-508. DOI: 10.1001/jama.2016.10260.
|
| [14] |
SEFEROVIĆ P M, COATS A J S, PONIKOWSKI P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure[J]. Eur J Heart Fail, 2020, 22(2): 196-213. DOI: 10.1002/ejhf.1673.
|
| [15] |
ZHOU M Z, ZHANG Y Y, SHI L, et al. Activation and modulation of the AGEs-RAGE axis: Implications for inflammatory pathologies and therapeutic interventions - A review[J]. Pharmacol Res, 2024, 206: 107282. DOI: 10.1016/j.phrs.2024.107282.
|
| [16] |
BUGGER H, ABEL E D. Molecular mechanisms of diabetic cardiomyopathy[J]. Diabetologia, 2014, 57(4): 660-671. DOI: 10. 1007/s00125-014-3171-6.
|
| [17] |
DING S J, XU S, MA Y, et al. Modulatory mechanisms of the NLRP3 inflammasomes in diabetes[J]. Biomolecules, 2019, 9(12): 850. DOI: 10.3390/biom9120850.
|
| [18] |
ZHENG X Q, WAN J, TAN G. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy[J]. Front Immunol, 2023, 14: 1151185. DOI: 10.3389/fimmu.2023.1151185.
|
| [19] |
CHEN Y, YE X Y, ESCAMES G, et al. The NLRP3 inflammasome: contributions to inflammation-related diseases[J]. Cell Mol Biol Lett, 2023, 28(1): 51. DOI: 10.1186/s11658-023-00462-9.
|
| [20] |
ZHANG X M, MIN X R, XIE H X, et al. Piperazine ferulate inhibits diabetic nephropathy by suppressing AGE/RAGE-mediated inflammatory signaling in rats and podocytes[J]. Front Pharmacol, 2024, 15: 1394369. DOI: 10.3389/fphar. 2024. 1394369.
|